Associate Prof. of Bioengineering, University of Pisa, Head of In-Vitro Models Group and NanoBioscopy Lab at the National Council of Research Institute of Clinical Physiology (CNR-IFC). Also involved in capacity building in the field of Biomedical Engineering, in association with UNECA and FABLAB Pisa .Author of over 100 peer-reviewed publications and of several patents on microfabrication and on bioreactors, co-founder of 2 high-tech companies.
Dr Alamian is Associate Dean for Health Studies and Associate Professor at University of Miami (UM) School of Nursing and Health Studies (SONHS). A fellow of the American College of Epidemiology, Dr Alamian oversees the public health and health science programs of the UM SONHS. Dr Alamian’s research interests include cluster-risk and theoretical modeling of risk behaviors and risk factors for chronic disease including metabolic syndrome, diabetes, and cardiovascular disease. He has been investigator on multiple NIH and state grants on pediatric obesity, metabolic syndrome, and biomarkers for chronic liver disease. Dr Alamian received his doctoral degree in public health, with specialization in epidemiology, from the University of Montreal School of Public Health. He completed a fellowship in public health through a Canadian Institutes of Health Research fellowship program at McGill University, and holds a master of science degree in pharmacy, with specialization in pharmacoepidemiology, from Laval University.
Senior Lecturer in Biological Sciences at the University of Huddersfield, since 2015. Previously Junior Research Fellow, College Lecturer In Biochemistry and various postdocs at the University of Oxford (2013-15). Working on DNA replication, genome integrity and transcription factors in human cancers (and also in prokaryotes). Additional interests in phylogenomics and novel protein expression systems.
Dr. Victor Coswig has a bachelor's degree, a Master's degree and a PhD in Physical Education from the Superior School of Physical Education of the Federal University of Pelotas (Pelotas, Brazil). He is currently Adjunct Professor and Researcher at the Physical Education and Sports Institute of the Federal University of Ceará (Fortaleza, Brazil), where he is investigating topic related to sports medicine and training.
His current research focuses on acute and chronic responses to exercise, training and sports practice, mainly, but not exclusive to combat sports performance.
Dr. Subrata Deb is Chair & Associate Professor in the Department of Pharmaceutical Sciences at Larkin University, United States. Previous to this, he held positions at the Roosevelt University, The University of British Columbia and Tripura University.
Dr. Deb received his Bachelor of Pharmacy degree from the Berhampur University and his Master of Pharmaceutical Sciences from the University of Mumbai. He received his Ph.D. in Pharmaceutical Sciences from The University of British Columbia and subsequently completed his postdoctoral fellowship from the Vancouver Prostate Centre, a National Centre of Excellence.
Dr. Deb’s primary research interests include Pharmacology, Toxicology, Pharmacogenomics, and Pharmacokinetics with special emphasis on Drug Metabolism and Drug Interactions.
Graduated in Medicine and Surgery at the University of Catania, Italy, specialist in Endocrinology and in Internal Medicine, PhD in Endocrinological and Metabolic Sciences. Full professor of Clinical Pathology, University "Magna Græcia" of Catanzaro, Italy.
Her scientific field of interest is related to endocrinology and metabolism, and to the study of novel biomarkers in human diseases. She is author of more than 120 scientific publications. Dr. Foti is a member of the Italian Society of Pathology and Laboratory Medicine (SIPMeL) and of the Italian Society of Pathology and Translational Medicine (SIPMeT).
Professor of Cardio-metabolic Health in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow. Lead an active multi-disciplinary research group investigating the effects of exercise and diet on the prevention and management of vascular and metabolic diseases from the molecular to the whole-body level. Major research interests include: why certain population groups appear to be particularly susceptible to the adverse effects of a ‘Westernised’ lifestyle, and how lifestyle interventions can modulate this excess risk; the interactions between physical activity, energy balance, body fatness and disease risk; and the mechanisms by which exercise regulates lipoprotein metabolism. Member of the NICE guidelines update committee for prevention of type 2 diabetes, and was member of development groups for the Scottish Intercollegiate Guidelines Network (SIGN) guidelines for the prevention and treatment of obesity and for prevention of cardiovascular disease. Past Chair of the British Association of Sport and Exercise Sciences (BASES) Division of Physical Activity for Health and Fellow of BASES. Director of the MSc programme in Sport and Exercise Science & Medicine at the University of Glasgow.
Dr. Gillespie is an evolutionary biologist with broad interests in organismal and molecular evolution. The major focus of his current research is deciphering the mechanisms by which obligate intracellular species of Rickettsiales (Alphaproteobacteria) invade, survive and replicate within eukaryotic cells.
In research funded by the National Institutes of Health, Dr. Gillespie utilizes phylogenetics, comparative genomics and bioinformatics to guide experimental research on various pathogenic species of Rickettsia and their associated arthropod vectors. His early research resulted in the reclassification of Rickettsia species and the identification of many lineage-specific pathogenicity factors. Through years of intense scrutinization of dozens of diverse rickettsial genomes, Dr. Gillespie and colleagues have described a large, dynamic mobilome for Rickettsia species, resulting in the identification of integrative conjugative elements as the vehicles for seeding Rickettsia genomes with many of the factors underlying obligate intracellular biology and pathogenesis. Via an iterative process of genome sequencing, phylogenomics, bioinformatics, and classical molecular biology and microbiology, Dr. Gillespie continues to lead and assist research projects on the characterization of rickettsial gene and protein function, as well as the description of cell envelope glycoconjugates.
Dr. Mahesh Gokara is a Postdoctoral Research Fellow in the Department of Cancer Biology at the Mayo Clinic. He has a Ph.D biochemistry with an experience of over 10 years in multidisciplinary research areas including biochemistry, biophysics and bioinformatics.
Dr. Hoy is Head of the Lipid Metabolism Laboratory in the School of Medical Sciences. His lab is a member of the Charles Perkins Centre. He is a Visiting Scientist in the Cancer Division of the Garvan Institute of Medical Research.
Dr. Hoy completed his BSc (Biomed Sc) and MSc (Research) at the University of Wollongong and PhD studies at the Garvan Institute of Medical Research. He performed postdoctoral training at Monash University where he was a recipient of an NHMRC Biomedical Australian Research Fellow (2010-2013).
Dr. Hoy's laboratory is focused on the regulation of lipid metabolism, predominantly fatty acid storage and utilisation, and how this may be perturbed in chronic disease states such as cancer, obesity and insulin resistance.
Manuel Jiménez López received his Ph.D. in the Department of Human Physiology, Histology, Pathological Anatomy, and Physical and Sports Education of the Faculty of Medicine of the University of Malaga (Spain) in 2011. Since 2012 he has been part of the International University of La Rioja (Spain) faculty. He received the "Dr. Fernández Pastor" for the best research in Sports Medicine in 2012 and was a finalist for this same award in 2013. As a researcher, he joined the "Research in Sports Science" group of the Biomedical Research Institute of Malaga, and the group research CTS-132 of the University of Malaga. He was the lead researcher in the TECNODEF-UNIR group from 2019 to 2023 and an honorary collaborating researcher in the Department of Basic Psychology and Language Sciences of the University College of London in 2019. Honorary collaborating professor at the Faculty of Medicine of the University of Malaga between 2009 and 2023. He has been invited as Key Speaker at the North American Symposium on Saliva Diagnostics in 2018, 2019, and 2020, at the Saliva Diagnostic Symposium of India in 2021 and 2022. He is an expert in saliva diagnostic techniques applied to performance control in professional sports, working with professional teams in football, cycling, athletics, badminton, judo, hockey, and basketball. He specializes in allostatic load, stress, psychophysical development, social neuroendocrinology, obesity, and affective neuroscience. As a teacher, he has taught classes on research methodology and clinical documentation, psychophysical development at school age, physical education, health, biomedical assessment of athlete performance, and anatomical bases of the human body. Currently, he is investigating salivary proteomics as a diagnostic method in neurodegenerative pathologies and the impact of stress on physical and mental health.
Dr. Sushil Kumar is a Research Assistant professor at the Oregon Health & Science University (OHSU), Portland Oregon. He obtained his PhD from Max Planck Institute for biochemistry, Munich Germany where he worked in supervision of Prof. Axel Ullrich for studying cancer cell signaling. He did his postdoctoral work in Prof. Reto Schwendener’s laboratory at University of Zurich where he developed liposomal drugs for targeted delivery of payloads to macrophages as novel cancer therapy approach. He joined OHSU in 2012 in Prof. Lisa Coussens' laboratory where he has continued his research for studying cancer inflammation and developing immunotherapeutic approaches for cancer. He is employing ex vivo as well as mouse models for understanding immune cell phenotype for analyzing their role in cancer progression and developing novel therapeutics as well as biomarkers for cancer.